Colon Cancer Screening Statistics in US 2026 | Key Facts

Colon Cancer Screening in the US 2026

Colon cancer screening represents one of the most effective preventive health interventions available in modern medicine, with the capability to reduce deaths from colorectal cancer by more than 60% through early detection and removal of precancerous polyps before they transform into cancer. As of 2026, approximately 63.5% of adults aged 45-75 in the United States are up-to-date with recommended colorectal cancer screening, according to the National Health Interview Survey (NHIS), reflecting steady progress toward the national goal of achieving 80% screening rates established by the National Colorectal Cancer Roundtable (NCCRT). The recommended screening age was lowered from 50 to 45 years in May 2021 by the U.S. Preventive Services Task Force (USPSTF), expanding the eligible screening population by approximately 19 million Americans and responding to the alarming rise in early-onset colorectal cancer cases among individuals under 50 years of age, where incidence rates have increased by 2.9% per year from 2013 to 2022.

Colorectal cancer remains the third most common cancer diagnosed in both men and women in the United States, with an estimated 158,850 new cases projected for 2026—including approximately 108,860 colon cancer cases and 49,990 rectal cancer cases—and approximately 55,230 deaths expected from the disease. However, when detected early through screening, the 5-year relative survival rate reaches 91% for localized colorectal cancer, compared to only 14% for advanced-stage disease, underscoring the critical importance of widespread screening adoption. The screening rate among adults aged 45 and older has increased substantially from 59% in 2021 to 65% in 2023, representing an additional 9.3 million adults screened between 2012 and 2018 alone. Despite this progress, significant disparities persist across racial and ethnic groups, with Hispanic adults showing the lowest screening rates at approximately 61.7% as of 2022, compared to 75.3% for non-Hispanic Black adults and 74.6% for non-Hispanic White adults, highlighting the ongoing need for targeted interventions to achieve health equity.

Interesting Facts About Colon Cancer Screening in the US 2026

Data Source: Centers for Disease Control and Prevention, National Cancer Institute, American Cancer Society, National Health Interview Survey, Behavioral Risk Factor Surveillance System – January 2026

Colon cancer screening rates in the US 2026 demonstrate significant progress over the past decade, with the percentage of adults aged 50-75 years who are up-to-date with screening reaching 72.6% in 2023—just 7.4 percentage points below the NCCRT’s 80% target. This represents a dramatic improvement from 52% in 2002 and 67.6% in 2016, translating to millions of additional Americans receiving potentially life-saving screening tests. The expansion of screening recommendations to include adults aged 45-49 added approximately 19 million people to the eligible screening population, though screening rates remain lower in this younger age group, with some estimates suggesting only 30-40% of adults aged 45-49 have been screened compared to higher rates in older age groups. The 3,617,246 patients screened at Federally Qualified Health Centers (FQHCs) in 2024 represents a 9.4% increase from 3,306,873 patients screened in 2023, demonstrating improved access to screening services for underserved populations.

The mortality benefits of widespread colorectal cancer screening are substantial and well-documented. The death rate from colorectal cancer has been dropping by approximately 1.5% per year in older adults during the past decade, with screening estimated to account for a significant fraction of this decline through both the detection and removal of precancerous polyps (preventing cancer from developing) and the identification of cancer at earlier, more treatable stages. Modeling studies estimate that achieving the 80% screening rate could prevent approximately 277,000 colorectal cancer cases and 203,000 colorectal cancer deaths by 2030, representing a substantial public health impact. However, the rising incidence of early-onset colorectal cancer in adults under 50 years—increasing by 2.9% annually from 2013 to 2022—has prompted the recommendation to begin screening at age 45, as approximately 20% of colorectal cancer diagnoses now occur in individuals under 50 years of age.

Colon Cancer Screening Methods in the US 2026

Data Source: U.S. Preventive Services Task Force, American Cancer Society, National Health Interview Survey, Behavioral Risk Factor Surveillance System – January 2026

Colonoscopy remains the dominant colorectal cancer screening method in the US 2026, accounting for approximately 60-65% of all screening procedures, with its popularity driven by its dual capability to both detect and immediately remove precancerous polyps during the same procedure. The 10-year screening interval for colonoscopy provides convenience for patients who prefer less frequent testing, though the procedure requires bowel preparation, sedation, and recovery time that may deter some eligible individuals. Research demonstrates that colonoscopy reduces colorectal cancer mortality by 68% for cancers in the left colon and rectum, with more modest benefits for right-sided colon cancers, while screening colonoscopy is associated with a 50% reduction in overall colorectal cancer incidence through the detection and removal of adenomatous polyps before they progress to invasive cancer.

Stool-based screening tests have experienced rapid growth in 2026 due to their non-invasive nature and the ability to complete testing at home without bowel preparation or time off work. The Fecal Immunochemical Test (FIT) has largely replaced older guaiac-based fecal occult blood tests (gFOBT) due to FIT’s superior sensitivity, elimination of dietary restrictions, and single-sample collection requirement. Multi-target stool DNA testing (mt-sDNA), marketed as Cologuard, combines FIT with detection of DNA mutations and methylation markers associated with colorectal cancer and advanced adenomas, offering 92% sensitivity for detecting cancer and 42% sensitivity for advanced precancerous lesions in clinical trials. The convenience of stool-based testing has proven particularly effective in increasing screening rates among previously unscreened individuals, with some health systems reporting that mailed FIT outreach programs achieve 30-40% completion rates among individuals who have declined or failed to complete colonoscopy, making stool-based testing a critical tool for closing the screening gap and achieving the 80% national goal.

Colon Cancer Screening Rates by Age in the US 2026

Data Source: National Health Interview Survey, Behavioral Risk Factor Surveillance System, Centers for Disease Control and Prevention – January 2026

Age-specific screening rates reveal significant variation across the colon cancer screening eligible population in the US 2026, with adults aged 65-75 years demonstrating the highest screening adherence at approximately 75-80%, likely reflecting the impact of Medicare coverage that eliminates most out-of-pocket costs for screening tests. Adults aged 55-64 show similarly robust screening rates of 70-75%, representing the age group most likely to have established relationships with primary care providers and heightened awareness of cancer screening recommendations. The newly expanded screening population of adults aged 45-49 exhibits substantially lower screening rates of approximately 30-45%, reflecting the recent nature of the guideline change, limited awareness among both patients and providers about the new recommendation, and the fact that many individuals in this age group do not have regular primary care engagement or perceive themselves as too young to need cancer screening.

The screening gap among younger eligible adults represents both a challenge and an opportunity for public health intervention in 2026. Research indicates that approximately 83% of unscreened individuals have never undergone any colorectal cancer screening test, suggesting that the primary barrier is initiating screening rather than maintaining screening adherence. Provider recommendation remains the strongest predictor of screening completion, with studies showing that individuals who receive a clear recommendation from their healthcare provider are 2-3 times more likely to complete screening compared to those who do not receive such guidance. However, a 2015 study found that racial minorities were more likely than White individuals to report lack of provider recommendation for colon cancer screening, contributing to observed disparities. The individualized screening recommendation for adults aged 76-85 recognizes that screening benefits must be weighed against life expectancy, comorbidities, and the 10-15 year lag time between polyp removal and cancer prevention, with screening generally not recommended for adults over 85 years or those with limited life expectancy under 10 years.

Colon Cancer Screening Disparities by Race and Ethnicity in the US 2026

Data Source: Behavioral Risk Factor Surveillance System, National Health Interview Survey, Centers for Disease Control and Prevention, American Cancer Society – January 2026

Racial and ethnic disparities in colon cancer screening persist as a major public health challenge in the US 2026, with Hispanic/Latino adults demonstrating the lowest screening rates at 61.7% in 2022—approximately 13 percentage points lower than Non-Hispanic White adults at 74.6%. Asian American and Pacific Islander (AAPI) adults show similarly low screening rates of approximately 62-65%, though notable heterogeneity exists within this diverse population, with some Asian ethnic subgroups demonstrating rates comparable to White adults while others lag significantly behind. Interestingly, Non-Hispanic Black adults achieved a screening rate of 75.3% in 2022, slightly exceeding White adults, though this population continues to experience the highest colorectal cancer incidence (45.7 per 100,000) and mortality rates (16.8 per 100,000) among all racial groups, suggesting that factors beyond screening—including access to high-quality colonoscopy, follow-up of abnormal screening results, and timely treatment—contribute to persistent outcome disparities.

Language barriers, immigration status, and length of time in the United States significantly impact colorectal cancer screening rates among immigrant populations. Hispanic adults with limited English proficiency (LEP) demonstrate substantially lower screening rates compared to English-proficient Hispanic adults and non-Hispanic White adults, even after controlling for education, insurance status, and number of chronic conditions. Foreign-born adults who have lived in the United States for less than 15 years show dramatically lower screening rates of 29-42% across all racial and ethnic groups, compared to 49-64% for those living in the US for 15 or more years, and 59-67% for U.S.-born individuals. These patterns suggest that acculturation, familiarity with the U.S. healthcare system, establishment of usual source of care, and time to accumulate health insurance all contribute to improved screening uptake. Insurance status represents perhaps the most powerful predictor of screening completion, with 2005 NHIS data showing that only 17.2% of uninsured adults aged 50-64 were up-to-date with screening, compared to 42.1% with Medicaid coverage and 45-49% with private insurance.

Colon Cancer Incidence and Mortality in the US 2026

Data Source: American Cancer Society, National Cancer Institute SEER Program, Centers for Disease Control and Prevention – January 2026

Colorectal cancer incidence and mortality rates in the US 2026 reflect both encouraging progress and concerning emerging trends. Among adults 50 years and older, colorectal cancer incidence rates have declined by approximately 1% annually from 2013 to 2022, continuing a downward trend that began in the mid-1980s and has resulted in over 30% reduction in age-adjusted incidence rates over approximately 35 years. This remarkable public health success is attributed to increased screening participation—which enables detection and removal of precancerous adenomatous polyps before they progress to invasive cancer—and to reductions in modifiable risk factors including smoking (which declined from 42% prevalence in 1965 to approximately 12% in 2023), red and processed meat consumption, and physical inactivity. Similarly, mortality rates have declined by approximately 1.5% per year in older adults over the past decade, reflecting both earlier detection through screening (when treatment is most effective) and improvements in surgical techniques, chemotherapy regimens, and targeted therapies.

However, these encouraging trends in older adults are counterbalanced by alarming increases in early-onset colorectal cancer (diagnosed before age 50), which has risen by 2.9% per year from 2013 to 2022. This increase has been observed across all racial and ethnic groups and affects both colon and rectal cancer, with rectal cancer showing particularly steep increases. The reasons for rising early-onset disease remain incompletely understood but likely involve changes in environmental and lifestyle factors including the obesity epidemic (with approximately 42% of U.S. adults now obese), increased consumption of ultra-processed foods, altered gut microbiome composition, decreased physical activity, and possibly environmental exposures to chemicals that disrupt endocrine function. Mortality rates among adults under 55 years have also increased by approximately 1% annually since the mid-2000s, reflecting both the rising incidence and the fact that younger patients may experience delayed diagnosis due to low clinical suspicion for cancer in this age group, resulting in more advanced-stage disease at presentation.

Colon Cancer Screening Benefits and Lives Saved in the US 2026

Data Source: American Cancer Society, New England Journal of Medicine, National Cancer Institute, USPSTF Evidence Reviews – January 2026

The life-saving benefits of colorectal cancer screening are among the most compelling in all of preventive medicine, with screening representing one of the few cancer screening tests that can actually prevent cancer rather than merely detecting it earlier. When precancerous adenomatous polyps are detected during colonoscopy or after an abnormal stool-based test prompts colonoscopy, their removal prevents progression to invasive cancer that would otherwise occur in approximately 5-10% of advanced adenomas over 10-15 years. This prevention mechanism, combined with early detection when cancer does develop, explains why colorectal cancer incidence among adults 50 years and older has declined by over 30% since the mid-1980s, with screening accounting for a substantial fraction of this reduction. The 91% five-year survival rate for localized colorectal cancer (detected while still confined to the colon or rectum) drops precipitously to 73% for regional disease (spread to nearby lymph nodes) and just 14% for distant-stage disease (metastatic to liver, lungs, or other organs), underscoring the critical importance of early detection.

Modeling studies provide powerful evidence of screening’s population-level impact, with researchers estimating that achieving the 80% screening rate target could prevent approximately 277,000 colorectal cancer cases and 203,000 colorectal cancer deaths by 2030. A landmark study from Kaiser Permanente Northern California published in the New England Journal of Medicine demonstrated that implementation of an organized, population-based screening program using mailed fecal immunochemical testing and on-request colonoscopy completely eliminated the historical disparity in colorectal cancer incidence and mortality between Black and White patients from 2006-2019. Prior to the screening program, Black patients experienced 60% higher incidence and significantly worse mortality compared to White patients; by 2019, after achieving high and equitable screening rates exceeding 75% in both groups, the incidence and mortality disparities had disappeared entirely. This study provides compelling real-world evidence that achieving high screening rates can eliminate racial disparities in colorectal cancer outcomes, suggesting that access to screening rather than biological differences primarily drives observed disparities.

Colon Cancer Screening Barriers and Challenges in the US 2026

Data Source: American Cancer Society, National Health Interview Survey, CDC, Gastroenterology journals – January 2026

Barriers to colorectal cancer screening in the US 2026 remain substantial despite decades of public health efforts, with insurance status representing the single most powerful predictor of screening completion. The approximately 27 million uninsured Americans as of 2023 face screening rates of only 17.2%, compared to 42-49% for insured individuals, with the $1,000-3,000 cost of colonoscopy without insurance coverage representing a prohibitive financial barrier for many families. Even among insured individuals, high-deductible health plans that require patients to pay the first $1,500-7,000 of healthcare costs out-of-pocket before insurance coverage begins may deter screening, particularly when individuals lack symptoms and perceive themselves as healthy. The Affordable Care Act mandate that health insurance plans cover USPSTF Grade A and B preventive services without cost-sharing has helped by eliminating co-pays and deductibles for screening tests, but this protection may be lost if polyps are found during colonoscopy and biopsy/removal occurs, triggering diagnostic billing codes that allow cost-sharing.

Provider-level barriers significantly impact screening rates, with lack of provider recommendation cited by patients as a major reason for non-screening. Research demonstrates that patients who receive clear recommendations from their healthcare providers are 2-3 times more likely to complete screening, yet a 2015 study found that racial and ethnic minorities were significantly more likely than White patients to report never receiving a screening recommendation from their provider. This disparity in provider communication contributes to observed differences in screening rates and may reflect implicit bias, time constraints during visits that limit preventive care discussions, or provider assumptions about patient preferences or ability to comply with screening. The 25% of American adults who lack a regular healthcare provider miss the opportunity for screening recommendations entirely, with this population disproportionately including young adults, men, racial and ethnic minorities, uninsured individuals, and those living in rural areas with limited primary care capacity.

Colon Cancer Screening Interventions and Programs in the US 2026

Data Source: National Colorectal Cancer Roundtable, American Cancer Society, CDC, Kaiser Permanente research – January 2026

Evidence-based interventions to increase colorectal cancer screening rates have proliferated in the US 2026, with mailed fecal immunochemical test (FIT) programs emerging as particularly effective for reaching previously unscreened populations. Health systems that implement organized mailed FIT outreach—directly sending FIT kits to eligible patients’ homes with simple instructions, prepaid return envelopes, and follow-up reminders—report completion rates of 30-40% among individuals who had previously declined or failed to complete colonoscopy screening. This approach removes multiple barriers including need for provider visits to obtain test kits, embarrassment about requesting screening, and time constraints, while the non-invasive nature of FIT testing appeals to individuals reluctant to undergo colonoscopy. Kaiser Permanente Northern California’s organized screening program, which combines mailed annual FIT with on-request colonoscopy and robust systems for tracking and following up abnormal results, achieved screening rates exceeding 75% and completely eliminated racial disparities in colorectal cancer incidence and mortality.

Patient navigation programs address the complex barriers that prevent eligible individuals from completing screening, particularly colonoscopy that requires scheduling procedures, arranging time off work, finding escorts home after sedation, and completing bowel preparation. Patient navigators—often community health workers with cultural and linguistic concordance with the populations they serve—provide personalized assistance including education about screening importance, help scheduling appointments, arrangement of transportation, connection to financial assistance programs, and support completing bowel preparation. Studies report that patient navigation increases colonoscopy completion rates by 20-30% compared to usual care, with particularly strong effects in underserved populations including racial and ethnic minorities, uninsured individuals, and those with limited English proficiency. The Federally Qualified Health Center network, which provides care to medically underserved populations, screened 3,617,246 patients for colorectal cancer in 2024—a 9.4% increase from 3,306,873 patients in 2023—demonstrating the impact of organized screening programs in safety-net settings.

Colon Cancer Screening Guidelines and Recommendations in the US 2026

Data Source: U.S. Preventive Services Task Force, American Cancer Society, American College of Gastroenterology, National Comprehensive Cancer Network – January 2026

The U.S. Preventive Services Task Force updated colorectal cancer screening recommendations in May 2021 to lower the recommended screening starting age from 50 to 45 years for adults at average risk, granting this recommendation a Grade A rating indicating high certainty that the net benefit is substantial. This change added approximately 19 million Americans aged 45-49 to the eligible screening population and responded to the alarming trend of rising colorectal cancer incidence in younger adults, with rates among adults under 50 increasing by 2.9% annually since 2013. The USPSTF provides patients and clinicians flexibility in choosing among multiple screening modalities including colonoscopy every 10 years, annual FIT testing, multi-target stool DNA testing every 3 years, flexible sigmoidoscopy every 5 years, flexible sigmoidoscopy every 10 years plus annual FIT, and CT colonography every 5 years, recognizing that the “best” test is the one that gets completed.

For adults aged 76-85 years, the USPSTF assigns a Grade C recommendation indicating that screening should be an individualized decision based on the patient’s health status, life expectancy, prior screening history, and personal preferences, as the net benefit of screening in this age group is smaller due to competing mortality risks and the 10-15 year lag time between polyp removal and cancer prevention. Adults over 85 years receive a Grade D recommendation against screening, as potential harms including complications from colonoscopy, overdiagnosis of indolent cancers, and burden of follow-up testing outweigh potential benefits in this population. High-risk individuals including those with inflammatory bowel disease (ulcerative colitis or Crohn’s disease), personal history of adenomatous polyps or colorectal cancer, first-degree relatives with colorectal cancer or advanced adenomas, or hereditary cancer syndromes (such as Lynch syndrome or familial adenomatous polyposis) require earlier and more frequent screening, typically beginning at age 40 or 10 years before the youngest family member’s diagnosis, whichever comes first.

State and Regional Colon Cancer Screening Variations in the US 2026

Data Source: Behavioral Risk Factor Surveillance System, CDC PLACES Data, State Cancer Profiles, American Cancer Society – January 2026

Geographic variations in colorectal cancer screening rates across the US 2026 reflect disparities in healthcare access, insurance coverage, provider availability, and cultural factors, with state-level screening rates ranging from approximately 50-70%. Northeastern states including Massachusetts, Connecticut, Rhode Island, and New Hampshire consistently report the highest screening rates, often exceeding 70%, driven by high rates of health insurance coverage (over 95% in Massachusetts due to that state’s healthcare reform), dense networks of primary care physicians and gastroenterologists, strong academic medical centers, and cultural emphasis on preventive health. Upper Midwest states including Minnesota, Wisconsin, and Iowa similarly demonstrate above-average screening rates, benefiting from high-quality integrated healthcare systems, robust safety-net programs, and populations with relatively high educational attainment and health literacy.

In contrast, Southern states including Mississippi, Louisiana, Arkansas, and Texas typically report screening rates 5-10 percentage points below the national average, reflecting higher uninsured rates (particularly in states that did not expand Medicaid under the Affordable Care Act), larger rural populations with limited access to gastroenterology services, higher poverty rates, and populations with lower educational attainment. Rural-urban disparities exist within states, with rural counties often reporting screening rates 5-15 percentage points lower than metropolitan areas due to limited colonoscopy capacity (gastroenterologists concentrate in cities), transportation barriers requiring drives of 50-100+ miles to reach endoscopy centers, and provider shortages that limit opportunities for screening recommendations. The CDC’s PLACES dataset provides county-level and even census tract-level screening estimates, revealing substantial variation even within cities, with low-income neighborhoods and predominantly minority communities showing lower screening rates than affluent predominantly White neighborhoods in the same metropolitan areas.

Future Directions for Colon Cancer Screening in the US 2026

Data Source: Clinical trial registries, FDA approvals, Gastroenterology literature, National Colorectal Cancer Roundtable – January 2026

Future directions for colorectal cancer screening in the US 2026 include exciting technological innovations that promise to make screening more acceptable, accessible, and effective. Blood-based screening tests that detect circulating tumor DNA, proteins, or other cancer-associated biomarkers represent a particularly promising frontier, with multiple tests in clinical trials showing ability to detect colorectal cancer with 80-90% sensitivity while maintaining high specificity to avoid false positives. A simple blood test that could be performed during routine primary care visits without special preparation or the need for stool sample collection could dramatically improve screening participation, particularly among individuals who find colonoscopy unacceptable and decline stool-based testing. Multi-cancer early detection (MCED) tests under development by multiple companies aim to screen for 10-50+ different cancer types with a single blood draw, potentially revolutionizing cancer screening by detecting multiple cancers simultaneously, though challenges remain regarding cost-effectiveness, follow-up of positive results, and potential for overdiagnosis.

Artificial intelligence (AI) applications are already improving colonoscopy quality through computer-aided detection (CADe) systems that provide real-time alerts when the endoscopy camera captures images containing possible polyps, helping gastroenterologists detect and remove lesions they might otherwise miss. Studies demonstrate that AI-assisted colonoscopy increases adenoma detection rates by 15-30%, potentially preventing more cancers through removal of additional polyps. Quality metrics including adenoma detection rates, cecal intubation rates, and withdrawal times are increasingly tracked and publicly reported, creating accountability for high-quality colonoscopy and helping patients identify high-performing endoscopists. Achieving the National Colorectal Cancer Roundtable’s 80% screening goal by 2026-2030 will require sustained multi-level interventions including continued expansion of mailed FIT programs, patient navigation, provider education, insurance coverage improvements, and health system transformation to systematically identify and reach unscreened eligible adults, with particular focus on eliminating persistent disparities affecting Hispanic, Asian American, Native American, uninsured, and rural populations.

Disclaimer: This research report is compiled from publicly available sources. While reasonable efforts have been made to ensure accuracy, no representation or warranty, express or implied, is given as to the completeness or reliability of the information. We accept no liability for any errors, omissions, losses, or damages of any kind arising from the use of this report.

Email ID:

Please enable JavaScript in your browser to complete this form.

Email

Email *

SUBSCRIBE